B cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-gamma.
Pathology
; 36(1): 69-76, 2004 Feb.
Article
in En
| MEDLINE
| ID: mdl-14757560
ABSTRACT
AIMS:
An important consideration in the design of a tumour vaccine is the ability of tumour-specific cytotoxic T lymphocytes (CTL) to recognise unmanipulated tumour cells in vivo. To determine whether B-CLL might use an escape strategy, the current studies compared B-CLL and normal B cell MHC class I expression.METHODS:
Flow cytometry, TAP allele PCR and MHC class I PCR were used.RESULTS:
While baseline expression of MHC class I did not differ, upregulation of MHC class I expression by B-CLL cells in response to IFN-gamma was reduced. No deletions or mutations of TAP 1 or 2 genes were detected. B-CLL cells upregulated TAP protein expression in response to IFN-gamma. Responsiveness of B-CLL MHC class I mRNA to IFN-gamma was not impaired.CONCLUSIONS:
The data suggest that MHC class I molecules might be less stable at the cell surface in B-CLL than normal B cells, as a result of the described release of beta(2)m and beta(2)m-free class I heavy chains from the membrane. This relative MHC class I expression defect of B-CLL cells may reduce their susceptibility to CTL lysis in response to immunotherapeutic approaches.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Histocompatibility Antigens Class I
/
Leukemia, Lymphocytic, Chronic, B-Cell
/
Interferon-gamma
Limits:
Aged
/
Humans
Language:
En
Journal:
Pathology
Year:
2004
Document type:
Article
Affiliation country:
Australia